Abstract
Objective
The aim of the present study was to evaluate the concentrations of activin A in the peritoneal fluid of women with epithelial (serous) ovarian cancer.
Methods
A group of 160 women was studied and divided in four subgroups as follows: 1) serous ovarian carcinoma (n = 32); 2) serous ovarian cystadenoma (n = 20); 3) endometriosis (n = 53); and 4) healthy controls (n = 55), including both fertile (n = 32) and postmenopausal women (n = 23). Specimens of peritoneal fluid were collected during surgical interventions, and activin A was quantified using a specific two-site enzyme immunoassay.
Results
Peritoneal fluid activin A concentrations in women with ovarian carcinoma were about five-fold higher than those found in the control group (median [interquartile range] = 7.60 [2.85–10.15] and 1.50 [1.00–2.50] ng/mL, respectively, P <.001). In contrast, the women with benign serous cystadenoma had peritoneal fluid activin A concentrations (1.50 [1.0–2.70] ng/mL) similar to those of the control group. High peritoneal fluid activin A levels (>2 multiples of the mean) distinguished carcinoma from cystadenoma with a sensitivity of 72% and a specificity of 80%. The follow-up of nine patients with stage IIIc ovarian cancer showed no apparent relationship between the peritoneal fluid activin A levels and overall survival. No significant difference in peritoneal fluid activin A concentrations between patients with endometriosis and control women was observed.
Conclusion
Most women with serous ovarian carcinoma had high concentrations of activin A in the peritoneal fluid, supporting a possible role of this growth factor in ovarian cancer.
References
Vale W, Rivier J, Vaughan J, et al. Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature 1986;321:776–9.
Luisi S, Florio P, Reis FM, Petraglia F. Expression and secretion of activin A: Possible physiological and clinical implications. Eur J Endocrinol 2001;145:225–36.
Petraglia F, Florio P, Luisi S, et al. Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues: High levels of serum activin A in women with endometrial and cervical carcinoma. J Clin Endocrinol Metab 1998;83:1194–200.
Harada K, Shintani Y, Sakamoto Y, Wakatsuki M, Shitsukawa K, Saito S. Serum immunoreactive activin A levels in normal subjects and patients with various diseases. J Clin Endocrinol Metab 1996;81:2125–30.
Reis FM, Cobellis L, Tameirao LC, et al. Serum and tissue expression of activin A in postmenopausal women with breast cancer. J Clin Endocrinol Metab 2002;87:2277–82.
Risbridger GP, Schmitt JF, Robertson DM. Activins and inhibins in endocrine and others tumors. Endocrine Rev 2001;22: 836–58.
Yamashita K, Yamoto M, Shikone T, Minami S, Nakano R. Immunohistochemical localization of inhibin and activin subunits in human epithelial ovarian tumors. Am J Obstet Gynecol 1999;180:316–22.
Zeng W, Sung CJ, Hanna I, et al. and subunits of inhibin/activin as sex cord-stromal differentiation markers. Int J Gynecol Pathol 1997;16:263–71.
Cobellis L, Cataldi P, Reis FM, et al. Gonadal malignant germ cell tumors express immunoreactive inhibin/activin subunits. Eur J Endocrinol 2001;145:779–84.
Welt CK, Lambert-Messerlian G, Zheng W, Crowley WF Jr, Schneyer AL. Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma. J Clin Endocrinol Metab 1997;82:3720–7.
Lambert-Messerlian GM, DePasquale SE, Maybruck WM, Steinhoff MM, Gajewski WH. Secretion of activin A in recurrent epithelial ovarian carcinoma. Gynecol Oncol 1999;74:93–7.
Menon U, Riley SC, Thomas J, et al. Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma. Br J Obstet Gynecol 2000;107:1069–74.
Florio P, Luisi S, Viganó P, et al. Healthy women and patients with endometriosis show high concentrations of inhibin A, inhibin B, and activin A in peritoneal fluid throughout the menstrual cycle. Hum Reprod 1998;13:2606–11.
Reis FM, Di Blasio AM, Florio P, Ambrosini G, Di Loreto C, Petraglia F. Evidence for local production of inhibin A and activin A in patients with ovarian endometriosis. Fertil Steril 2001;75:367–73.
Ala-Fossi SL, Maenpaa J, Blauer M, Tuohimaa P, Punnonen R. Inhibin A, B and pro-alphaC in serum and peritoneal fluid in postmenopausal patients with ovarian tumors. Eur J Endocrinol 2000;142:334–9.
Ogawa K, Funaba M, Mathews LS, Mizutani T. Activin A stimulates type IV collagenase (matrix metalloproteinase-2) production in mouse peritoneal macrophages. J Immunol 2000;165:2997–3003.
Ito I, Minegishi T, Fukuda J, Shinozaki H, Auersperg N, Leung PCK. Presence of activin signal transduction in normal ovarian cells and epithelial ovarian carcinoma. Br J Cancer 2000;82:1415–20.
Zheng W, Lauchlan SC. Inhibin and activin: Their roles in ovarian tumorigenesis and their diagnostic utility in surgical pathology practice. Appl Immunohistochem 1999;7:29–38.
Coerver KA, Woodruff TK, Finegold MJ, Mather J, Bradley A, Matzuk MM. Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice. Mol Endocrinol 1996;10:534–43.
Zeng W, Luo MP, Welt C, et al. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. Gynecol Oncol 1998;69:23–31.
Muttukrishna S, Fowler PA, George L, Groome NP, Knight PG. Changes in peripheral serum levels of total activin A during the human menstrual cycle and pregnancy. J Clin Endocrinol Metab 1996;81:3328–34.
Loria P, Petraglia F, Concari M, et al. Influence of age and sex on serum concentrations of total dimeric activin A. Eur J Endocrinol 1998;139:487–92.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cobellis, L., Reis, F.M., Luisi, S. et al. High Concentrations of Activin A in the Peritoneal Fluid of Women With Epithelial Ovarian Cancer. Reprod. Sci. 11, 203–206 (2004). https://doi.org/10.1016/j.jsgi.2003.10.008
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.jsgi.2003.10.008